N/A
N=1,664
Procalcitonin Antibiotic Consensus Trial (ProACT)
Lower Respiratory Tract Infection (LRTI)
Bottom Line
View on ClinicalTrials.gov: NCT02130986 ↗Enrolled (actual)
1,664
Serious AEs
1.4%
Results posted
Jan 2019
Primary outcome: Primary: Total Antibiotic Exposure Days — 4.2; 4.3 days — p=0.87
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Procalcitonin level (Other); Results of procalcitonin (PCT) level to treating clinician (Other); Provide procalcitonin guideline to treating clinician (Other); Telephone Visit (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Pittsburgh
- Primary completion
- Jul 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Antibiotic Exposure Days |
4.2; 4.3 | 0.87 |
| PRIMARY Number of Participants With Any Adverse Outcome |
96; 109 | <0.001 sig |
| SECONDARY Antibiotic Prescription in Emergency Department(ED) |
282; 321 | — |
Summary
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory Tract Infection (LRTI).
Eligibility Criteria
Inclusion Criteria
- ≥ 18 years old
- A primary clinical diagnosis in the ED of acute LRTI ( 1 dose within 72 hours prior to ED presentation)
- Current vasopressor use
- Mechanical ventilation (via endotracheal tube)
- Known severe immunosuppression
- Accompanying non-respiratory infections
- Known lung abscess or empyema
- Chronic dialysis
- Metastatic cancer
- Surgery in the past 7 days (excluding minor surgery such as skin biopsy)
- Incarcerated or homeless
- Enrolled in ProACT in the past 30 days
Data sourced from ClinicalTrials.gov (NCT02130986). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.